YOLFTbeta
Lukas Biomedical Inc.

Lukas Biomedical Inc.

6814 · TWO · Healthcare / Biotechnology

18.10TWD+0.70 (+4.02%)

Price History

Full chart

Market Stats

Previous Close17.40
Open16.75
Day Range16.55 – 18.10
52-Week Range17.30 – 32.50
Volume68.02K
Market Cap770.48M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.20
Dividend Yield0.00%
Beta0.09
50-Day Avg20.55
200-Day Avg24.99

About

Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases building equipment. In addition, the company involved in the new immune cell research and development, new product development, clinical trials, and production of cell reagents; and provision of brand management and medical management services. Lukas Biomedical Inc. was founded in 2002 and is based in New Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOChaoan Liu
  • Employees87
  • HeadquartersNo. 14-16, Zhongxiao Road, New Taipei City, Taiwan, 220065, Taiwan
  • Websitehttps://www.lukas-biomedical.com

Leadership

  • Chaoan LiuManager
  • Wen Xuan ChengAccounting Supervisor
  • Mr. Ping-Chung LiuChief Medical Officer & Head of the Cell Products Department

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue152.89M181.41M157.62M184.79M231.83M189.83M179.49M
Growth (%)-+18.65%-13.12%+17.24%+25.46%-18.12%-5.44%
Cost of Revenue52.73M62.96M61.55M86.88M97.94M76.71M71.63M
Gross Profit100.16M118.45M96.06M97.91M133.89M113.12M107.87M
Gross Margin65.51%65.29%60.95%52.98%57.75%59.59%60.10%
Operating Expense107.19M124.93M139.13M146.37M177.45M205.25M189.01M
Operating Income-7.03M-6.48M-43.06M-48.47M-43.56M-92.14M-81.15M
Operating Margin-4.60%-3.57%-27.32%-26.23%-18.79%-48.54%-45.21%
EBITDA47.66M43.28M-361.00K-10.93M-12.57M-62.88M-55.52M
EBITDA Margin31.17%23.86%-0.23%-5.92%-5.42%-33.12%-30.93%
Net Income-6.99M-10.54M-49.49M-50.07M-47.35M-94.38M-85.63M
Net Income Margin-4.57%-5.81%-31.40%-27.10%-20.43%-49.72%-47.71%
R&D29.20M35.39M54.98M55.92M77.33M94.73M82.78M
R&D as % of Total Revenue19.10%19.51%34.88%30.26%33.36%49.91%46.12%
Interest Expense5.19M4.83M4.42M2.92M3.07M3.04M3.21M
Interest Expense % of Total Revenue3.40%2.66%2.80%1.58%1.33%1.60%1.79%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets556.13M523.61M531.24M479.67M441.19M476.50M426.80M
Total Liabilities254.71M232.73M244.57M152.18M161.06M150.68M186.62M
Total Equity301.42M290.88M286.68M327.49M280.13M325.82M240.19M
Cash40.03M39.04M64.81M40.26M31.80M64.71M34.75M
Total Debt230.07M212.29M221.47M112.42M125.86M115.20M-
Net Debt190.04M173.25M156.66M72.16M94.06M50.48M88.70M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow59.05M29.03M-16.16M-7.44M-11.75M-70.53M-61.43M
Investing Cash Flow-62.71M-10.86M-10.33M2.87M-1.66M-9.79M-
Financing Cash Flow-8.86M-19.16M52.25M-19.98M4.94M113.24M-
Capital Expenditure63.87M8.99M10.03M2.98M2.66M6.81M8.52M
Free Cash Flow-4.81M20.05M-26.18M-10.41M-14.41M-77.35M-69.95M
FCF to OCF-8.15%69.04%162.07%140.02%122.64%109.66%113.87%

Key Statistics & Ratios

Market Cap770.48M
Enterprise Value984.05M
Trailing P/E0.00
Forward P/E0.00
Price / Sales4.53
Price / Book3.98
EPS-2.20
Book Value4.57
Revenue (TTM)170.01M
Gross Profit (TTM)101.81M
EBITDA-76.48M
Profit Margin-54.14%
Operating Margin-60.04%
Return on Equity-38.79%
Return on Assets-11.76%
Shares Outstanding41.87M
Shares Float13.23M
Beta0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%